Biological Activity: Ticlopidine hydrochloride is a hydrochloride salt form of ticlopidine which is a selective P2Y12 receptor antagonist. Ticlopidine hydrochloride inhibits ADP-induced platelet aggregation and exhibits antithrombotic activity following oral administration in vivo. Ticlopidine hydrochloride produces time- and dose-dependent inhibition of both platelet aggregation and release of platelet granule constituents as well as prolongation of bleeding time. Ticlopidine hydrochloride interferes with platelet membrane function by preventing platelet-fibrinogen binding and subsequent platelet-platelet interactions. Ticlopidine hydrochloride is rapidly absorbed with peak levels (Tmax) occurring about 2 after dose. Ticlopidine hydrochloride is greater than 80% absorbed. Administration after meals results in a 20% increase in the AUC. Ticlopidine hydrochloride is 98% bound to plasma proteins. Ticlopidine hydrochloride is metabolized extensively by the liver. Only trace amounts of ticlopidine are detected in urine. [1]References on Ticlopidine HCl[1] Arterioscler Thromb Vasc Biol., 2008 Mar, 28(3):s33-8
Harmful (Xn)